Literature DB >> 15955857

Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study.

Luigi Grazioli1, Giovanni Morana, Miles A Kirchin, Günther Schneider.   

Abstract

PURPOSE: To prospectively determine the accuracy of differentiating benign focal nodular hyperplasia (FNH) from hepatic adenoma (HA) and liver adenomatosis (LA) by using gadobenate dimeglumine-enhanced magnetic resonance (MR) imaging.
MATERIALS AND METHODS: The ethics committee at each center approved the study, and all patients provided informed consent. Seventy-three patients with confirmed FNH and 35 patients with confirmed HA (n = 27) or LA (n = 8) underwent MR imaging before (T2-weighted half-Fourier rapid acquisition with relaxation enhancement or T2-weighted fast spin-echo and T1-weighted gradient-echo [GRE] sequences) and at 25-30 seconds (arterial phase), 70-90 seconds (portal venous phase), 3-5 minutes (equilibrium phase), and 1-3 hours (delayed phase) after (T1-weighted GRE sequences only, with or without fat suppression) bolus administration of 0.1 mmol per kilogram of body weight gadobenate dimeglumine. The enhancement of 235 lesions (128 FNH, 32 HA, and 75 LA lesions) relative to the normal liver parenchyma was assessed. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and overall accuracy for the differentiation of FNH from HA and LA were determined.
RESULTS: Hyper- and isointensity on T2-weighted and iso- and hypointensity on T1-weighted GRE images were noted for 177 (88.9%) of 199 lesions visible on unenhanced images. On dynamic phase images after contrast material administration, 231 (98.3%) of 235 lesions showed rapid strong enhancement during the arterial phase and appeared hyper- to isointense during portal venous and equilibrium phases. Accurate differentiation of FNH from HA and LA was not possible on the basis of precontrast or dynamic phase images alone. At 1-3 hours after contrast material enhancement, 124 (96.9%) of 128 FNHs appeared hyper- or isointense, while 107 (100%) HA and LA lesions appeared hypointense. The sensitivity, specificity, PPV, NPV, and overall accuracy for the differentiation of FNH from HA and LA were 96.9%, 100%, 100%, 96.4%, and 98.3%, respectively.
CONCLUSION: Accurate differentiation of FNH from HA and LA is achievable on delayed T1-weighted GRE images after administration of gadobenate dimeglumine. Copyright RSNA, 2005

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15955857     DOI: 10.1148/radiol.2361040338

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  76 in total

1.  MRI findings of uncommon non-hepatocyte origin primary liver tumours with pathological correlation.

Authors:  Y C Kim; M-S Park; Y E Chung; M-J Kim; Y N Park; J-H Kang; K A Kim; K W Kim
Journal:  Br J Radiol       Date:  2010-10-05       Impact factor: 3.039

Review 2.  Focal nodular hyperplasia--a review of myths and truths.

Authors:  Christopher B Nahm; Kevin Ng; Philip Lockie; Jaswinder S Samra; Thomas J Hugh
Journal:  J Gastrointest Surg       Date:  2011-09-30       Impact factor: 3.452

3.  High resolution navigated three-dimensional T₁-weighted hepatobiliary MRI using gadoxetic acid optimized for 1.5 Tesla.

Authors:  Scott K Nagle; Reed F Busse; Anja C Brau; Jean H Brittain; Alex Frydrychowicz; Yuji Iwadate; Scott B Reeder
Journal:  J Magn Reson Imaging       Date:  2012-05-30       Impact factor: 4.813

Review 4.  Focal nodular hyperplasia and hepatic adenoma: current diagnosis and management.

Authors:  Agustin Cristiano; Agustin Dietrich; Juan Carlos Spina; Victoria Ardiles; Eduardo de Santibañes
Journal:  Updates Surg       Date:  2013-06-27

5.  Malignant focal liver lesions at contrast-enhanced ultrasonography and magnetic resonance with hepatospecific contrast agent.

Authors:  M D'Onofrio; S Crosara; R De Robertis; S Canestrini; V Cantisani; G Morana; R Pozzi Mucelli
Journal:  Ultrasound       Date:  2013-12-13

6.  Iso- or hyperintensity of hepatocellular adenomas on hepatobiliary phase does not always correspond to hepatospecific contrast-agent uptake: importance for tumor subtyping.

Authors:  Edouard Reizine; Maxime Ronot; Frederic Pigneur; Yvonne Purcell; Sebastien Mulé; Marco Dioguardi Burgio; Julien Calderaro; Giuliana Amaddeo; Alexis Laurent; Valérie Vilgrain; Alain Luciani
Journal:  Eur Radiol       Date:  2019-04-01       Impact factor: 5.315

7.  Optimized high-resolution contrast-enhanced hepatobiliary imaging at 3 tesla: a cross-over comparison of gadobenate dimeglumine and gadoxetic acid.

Authors:  Alex Frydrychowicz; Scott K Nagle; Sharon L D'Souza; Karl K Vigen; Scott B Reeder
Journal:  J Magn Reson Imaging       Date:  2011-07-12       Impact factor: 4.813

8.  Gadobenate-dimeglumine-enhanced magnetic resonance imaging for hepatic lesions in children.

Authors:  Govind B Chavhan; Erika Mann; Binita M Kamath; Paul S Babyn
Journal:  Pediatr Radiol       Date:  2014-04-27

9.  Quantitative correlation between uptake of Gd-BOPTA on hepatobiliary phase and tumor molecular features in patients with benign hepatocellular lesions.

Authors:  Edouard Reizine; Giuliana Amaddeo; Frederic Pigneur; Laurence Baranes; François Legou; Sebastien Mulé; Benhalima Zegai; Vincent Roche; Alexis Laurent; Alain Rahmouni; Julien Calderaro; Alain Luciani
Journal:  Eur Radiol       Date:  2018-05-02       Impact factor: 5.315

Review 10.  Clinical value of MRI liver-specific contrast agents: a tailored examination for a confident non-invasive diagnosis of focal liver lesions.

Authors:  Ahmed Ba-Ssalamah; Martin Uffmann; Sanjai Saini; Nina Bastati; Christian Herold; Wolfgang Schima
Journal:  Eur Radiol       Date:  2008-09-23       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.